tbuckley/cabot-search huggingface dataset:
Consideration of Sex Differences in Medicine to Improve Health Care and Patient Outcomes
Authors: Marianne J. Legato, Paula A. Johnson, JoAnn E. Manson
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Differential Gene Expression Analysis Predicts For Response To Bortezomib In The Treatment Of Steroid Refractory Chronic Graft-Versus-Host Disease (cGVHD)
Authors: Alan M Miller, Reva Schneider, Estil A. Vance, Edward Agura, Sheila Powell, Virginia Pascual, Indira Munagala, Huanying Qin
Journal: Blood (2013)
Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Authors: Wendy Stock, Karen WL Yee, Eunice S. Wang, Sari Enschede, Joyce Steinberg, Rod Humerickhouse, Qin Qin, Jiang Qian, Yi-Lin Chiu, Neeraj Gupta, Rajendra Pradhan
Journal: Blood (2008)
ROL DE CEH-EUS EN EL DIAGNÓSTICO DIFERENCIAL DE LAS LESIONES SUBMUCOSAS GASTROINTESTINALES
Authors: M Abu-Suboh Abadia, M Masachs Peracaula, J Armengol Bertroli, MJ Pascasio, M Pigrau, A Benages Curell, MD Castillo Cejas, D Sihuay, J Dot Bach, JR Armengol Miró
Journal: Endoscopy (2016)

Introducción: Establecer un diagnóstico específico de las lesiones submucosas gastrointestinales (LSGI) es de vital importancia para el tratamiento médico-quirúrgico, o para su vigilancia endoscópica posterior. En la actualidad el EUS permite un diagnóstico de manera menos invasiva de estas lesiones, a pesar que la histología se considera el gold standard para el diagnóstico de las LSGI.
COLANGIOPANCREATOSCOPIA MEDIANTE UN OPERADOR: EXPERIENCIA EN UN CENTRO TERCIARIO Y VENTAJAS DEL SISTEMA SPYGLASS® DIGITAL
Authors: V Pons Beltran, N Alonso-Lázaro, A Barrios Barrios, M Ponce Romero, L Argüello Viúdez, D Ramos Soler, J Pérez Rojas, M Bustamante-Balén
Journal: Endoscopy (2016)

Introducción: La colangiopancreatoscopia guiada por un operador (SOCP) es una herramienta esencial tanto para el estudio de las estenosis indeterminadas de la vía biliar como para el tratamiento de litiasis pancreáticas y biliares complejas.
Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L.
Authors: Emanuela M. Ghia, Laura Z. Rassenti, George F. Widhopf, Gregg J. Silverman, Donna S. Neuberg, Michael J. Keating, William G. Wierda, John G. Gribben, Jennifer R. Brown, Kanti R. Rai, John C. Byrd, Neil E. Kay, Andrew W. Greaves, Thomas J. Kipps
Journal: Blood (2007)
Mechanisms through Which Hypoxia-Induced Caveolin-1 Drives Tumorigenesis and Metastasis in Hepatocellular Carcinoma
Authors: Xiaowen Mao, Sivia Yuen Sze Wong, Edith Yuk Ting Tse, Frankie Chi Fat Ko, Sze Keong Tey, Yin Shan Yeung, Kwan Man, Regina Cheuk-Lam Lo, Irene Oi-Lin Ng, Judy Wai Ping Yam
Journal: Cancer Research (2016)

In solid tumors, hypoxia triggers an aberrant vasculogenesis, enhances malignant character, and elevates metastatic risk. The plasma membrane organizing protein caveolin-1 (Cav1) is increased in a variety of cancers, including hepatocellular carcinoma (HCC), where it contributes to metastatic capability. However, the reason for elevation of Cav1 in tumor cells and the mechanistic basis for its contributions to metastatic risk are not fully understood. Here, we show that in HCC cells, hypoxia elevates expression of Cav1, which then acts through the calcium-binding protein S100P to promote metastasis. Hypoxic regions of HCC xenografts displayed elevated expression of Cav1. Hypoxia promoted HCC cell migration and invasion and distant pulmonary metastases, whereas Cav1 silencing abolished these effects. Gene expression profiling revealed that hypoxia-induced Cav1 functioned as a positive regulator of S100P via activation of the NF-κB pathway. S100P elevation under hypoxic conditions was abrogated by silencing of Cav1 or NF-κB function. Conversely, restoring S100P in Cav1-silenced cells rescued the migratory potential of HCC cells along with tumor formation and lung metastasis. In clinical specimens of HCC, we observed S100P overexpression to correlate with venous invasion, microsatellites, direct liver invasion, and absence of tumor encapsulation. Collectively, our findings demonstrated how hypoxia-induced expression of Cav1 in HCC cells enhances their invasive and metastatic potential. Cancer Res; 76(24); 7242-53. ©2016 AACR.
Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan
Authors: Norio Sugaya, Masayoshi Shinjoh, Chiharu Kawakami, Yoshio Yamaguchi, Makoto Yoshida, Hiroaki Baba, Mayumi Ishikawa, Mio Kono, Shinichiro Sekiguchi, Takahisa Kimiya, Keiko Mitamura, Motoko Fujino, Osamu Komiyama, Naoko Yoshida, Kenichiro Tsunematsu, Atsushi Narabayashi, Yuji Nakata, Akihiro Sato, Nobuhiko Taguchi, Hisayo Fujita, Machiko Toki, Michiko Myokai, Ichiro Ookawara, Takao Takahashi
Journal: Eurosurveillance (2016)

The 2014/15 influenza season in Japan was characterised by predominant influenza A(H3N2) activity; 99% of influenza A viruses detected were A(H3N2). Subclade 3C.2a viruses were the major epidemic A(H3N2) viruses, and were genetically distinct from A/New York/39/2012(H3N2) of 2014/15 vaccine strain in Japan, which was classified as clade 3C.1. We assessed vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children aged 6 months to 15 years by test-negative case-control design based on influenza rapid diagnostic test. Between November 2014 and March 2015, a total of 3,752 children were enrolled: 1,633 tested positive for influenza A and 42 for influenza B, and 2,077 tested negative. Adjusted VE was 38% (95% confidence intervals (CI): 28 to 46) against influenza virus infection overall, 37% (95% CI: 27 to 45) against influenza A, and 47% (95% CI: -2 to 73) against influenza B. However, IIV was not statistically significantly effective against influenza A in infants aged 6 to 11 months or adolescents aged 13 to 15 years. VE in preventing hospitalisation for influenza A infection was 55% (95% CI: 42 to 64). Trivalent IIV that included A/New York/39/2012(H3N2) was effective against drifted influenza A(H3N2) virus, although vaccine mismatch resulted in low VE.
PDGFRA Activity Is Mediated by An Autocrine Loop in Peripheral T-Cell Lymphoma/Not Otherwise Specified (PTCL/NOS).
Authors: Maura Rossi, Francesco Alviano, Antonella Laginestra, Pierluigi Tazzari, Francesca Ricci, Aurora Esposito, Claudio Agostinelli, Maria Teresa Sista, Anna Gazzola, Claudia Mannu, Simona Righi, Maria Rosaria Sapienza, Gian Paolo Bagnara, Sylvia Hartmann, Martin Leo Hansmann, Pier Luigi Zinzani, Stefano Aldo Pileri, Pier Paolo Piccaluga
Journal: Blood (2009)
P1.02-056 Tumor Heterogeneity in Lesion Specific Response Creates ROS1 Fusion Mediating Resistance to Gefitinib in EGFR 19 Deletion Lung Adenocarcinoma
Authors: Xiaomin Niu, Xinghao Ai, Zhiwei Chen, Shaochuan Chuai, Yi Yang, Shun Lu
Journal: Journal of Thoracic Oncology (2017)
RESECCIÓN ENDOSCÓPICA TRANSMURAL (ENDOSCOPIC FULL-THICKNESS RESECTION) PARA LESIONES COLÓNICAS. EXPERIENCIA INICIAL EN 3 CENTROS DE CATALUÑA (2015 – 2016)
Authors: HI Uchima Koecklin, D Barquero Declara, A Fernández Simón, A Mata Bilbao, M Figa, C Huertas Nadal, M Hombrados, JC Espinos Perez
Journal: Endoscopy (2016)

Resección endoscópica transmural (endoscopic full-thickness resection) para lesiones colónicas. Experiencia inicial en 3 centros de cataluña (2015 – 2016).
CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α
Authors: Xi Tian, Minh Nguyen, Henry P. Foote, Joseph M. Caster, Kyle C. Roche, Christian G. Peters, Pauline Wu, Lata Jayaraman, Edward G. Garmey, Joel E. Tepper, Scott Eliasof, Andrew Z. Wang
Journal: Cancer Research (2016)

Novel agents are needed to improve chemoradiotherapy for locally advanced rectal cancer. In this study, we assessed the ability of CRLX101, an investigational nanoparticle-drug conjugate containing the payload camptothecin (CPT), to improve therapeutic responses as compared with standard chemotherapy. CRLX101 was evaluated as a radiosensitizer in colorectal cancer cell lines and murine xenograft models. CRLX101 was as potent as CPT in vitro in its ability to radiosensitize cancer cells. Evaluations in vivo demonstrated that the addition of CRLX101 to standard chemoradiotherapy significantly increased therapeutic efficacy by inhibiting DNA repair and HIF1α pathway activation in tumor cells. Notably, CRLX101 was more effective than oxaliplatin at enhancing the efficacy of chemoradiotherapy, with CRLX101 and 5-fluorouracil producing the highest therapeutic efficacy. Gastrointestinal toxicity was also significantly lower for CRLX101 compared with CPT when combined with radiotherapy. Our results offer a preclinical proof of concept for CRLX101 as a modality to improve the outcome of neoadjuvant chemoradiotherapy for rectal cancer treatment, in support of ongoing clinical evaluation of this agent (LCC1315 NCT02010567). Cancer Res; 77(1); 112-22. ©2016 AACR.
P0966 : Adipose tissue inflammation occurs prior to liver inflammation in mice fed a high-fat diet
Authors: F. Sheedfar, R.A. Van Der Heijden, M.C. Morrison, P.H. Hommelberg, S. Youssef, N. Gruben, A. De Bruin, M.H. Hofker, R. Kleemann, D.P. Koonen, P. Heeringa
Journal: Journal of Hepatology (2015)
Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association
Authors: Biykem Bozkurt, David Aguilar, Anita Deswal, Sandra B. Dunbar, Gary S. Francis, Tamara Horwich, Mariell Jessup, Mikhail Kosiborod, Allison M. Pritchett, Kumudha Ramasubbu, Clive Rosendorff, Clyde Yancy
Journal: Circulation (2016)
UTILIDAD DE LA INDOMETACINA RECTAL EN LA PREVENCIÓN DE LA PANCREATITIS AGUDA POSTCPRE EN PACIENTES CON ESFINTEROTOMÍA PREVIA
Authors: AD Polanco Jimenez, A Lopez Serrano, CA Amurrio Gonzalez, A Pascual Romero, MJ Suarez Davalos, I Ortiz Polo, P Latorre Año, C Garcia Orts, J Hervas Martin, E Moreno Osset
Journal: Endoscopy (2016)

Introducción: La pancreatitis aguda es la complicación más frecuente de la CPRE. Diversos estudios, incluyendo las últimas guías de la Sociedad Europea de Endoscopia Gastrointestinal (ESGE), apoyan el uso de 100 mg de indometacina rectal para prevenir esta complicación; sin embargo, existe controversia acerca de su beneficio en la prevención de la pancreatitis aguda postCPRE (PAP). Además, existe poca información acerca de si esta profilaxis es igualmente eficaz en los pacientes con esfinterotomía previa.
LA SEPTOTOMÍA ENDOSCÓPICA CON EL SISTEMA LIGASURE™ ES UN MÉTODO EFICAZ Y SEGURO PARA EL TRATAMIENTO DEL DIVERTÍCULO DE ZENKER
Authors: E Sáez González, N Alonso Lázaro, N García Morales, B Navarro Navarro, MT Blázquez Martínez, J Herreras López, M Ponce Romero, M Bustamante Balen, L Argüello Viudez, V Pons Beltrán
Journal: Endoscopy (2016)

Antecedentes: La crico-faringo-mío-septomía endoscópica (CFMST) es una técnica para el tratamiento del divertículo de Zenker (DZ). La experiencia con sistemas de corte-sellado vascular computarizado (tipo LigaSure™) es escasa.
Government is set to miss target to recoup £500m from treating overseas visitors
Authors: Gareth Iacobucci
Journal: BMJ (2016)

The government is unlikely to meet its target to recover £500m (€560m; $610m) a year from the cost of treating overseas visitors who are not entitled to free NHS hospital treatment by 2017-18, the National Audit Office has concluded.1

The Department of Health in England launched a programme in 2014 to extend the scope of charging for overseas patients and implement existing regulations more effectively to tackle concerns that the NHS was “overly generous” to overseas visitors.2

In a progress report, the NAO found that the total amount of income identified had almost trebled since the start of the scheme, from £97m …
TCT-510 Multislice computed tomography imaging of Sapien 3 transcatheter heart valve implantation in different bicuspid aortic valve anatomies
Authors: Hiroyuki Kawamori, Yigal Abramowitz, Tarun Chakravarty, Yoshio Maeno, YOSHIO KAZUNO, Nobuyuki Takahashi, Mohammad Kashif, Geeteshwar Mangat, Wen Cheng, Raj Makkar, Hasan Jilaihawi
Journal: Journal of the American College of Cardiology (2016)
Judging the Past: How History Should Inform Bioethics
Authors: David A. Gorelick
Journal: Annals of Internal Medicine (2016)

Letters1 November 2016Judging the Past: How History Should Inform BioethicsDavid A. Gorelick, MD, PhDDavid A. Gorelick, MD, PhDFrom University of Maryland School of Medicine, Baltimore, Maryland.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0332 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I believe that the otherwise cogent reasoning in Lerner and Caplan's commentary on how history should inform bioethics (1) suffers from 1 logical flaw, namely, ignoring the distinction between research and clinical care. All but 1 of the past ethical violations that they discuss are clearly research projects—that is, activities designed to yield generalizable knowledge. However, 1 example that they describe, “lobotomy to treat mental illness,” is not research but rather clinical care designed to benefit the individual patient. Although hindsight may show that this treatment usually was not beneficial and was perhaps often harmful, the physicians ...Reference1. Lerner BH, Caplan AL. Judging the past: how history should inform bioethics. Ann Intern Med. 2016;164:553-7. [PMID: 27089070]. doi:10.7326/M15-2642 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Maryland School of Medicine, Baltimore, Maryland.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0332. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoJudging the Past: How History Should Inform Bioethics Barron H. Lerner and Arthur L. Caplan Judging the Past: How History Should Inform Bioethics Barron H. Lerner and Arthur L. Caplan Judging the Past: How History Should Inform Bioethics Michele A. Riva Metrics 1 November 2016Volume 165, Issue 9Page: 674-675KeywordsBioethicsConflicts of interestDisclosureHistory of medicineMyocardial infarctionReasoningResearch ethics ePublished: 1 November 2016 Issue Published: 1 November 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
TCT-237 Outcomes After Successful PCI of Severely Calcified Lesions Using Rotational Atherectomy, Cutting Balloon, or Balloon Angioplasty only Before Second-Generation Drug-Eluting Stent Implantation
Authors: Bjorn Redfors, Philippe Généreux, Akiko Maehara, Ajay Kirtane, Rushad Dordi, Bernhard Witzenbichler, Giora Weisz, Thomas Stuckey, Michael Rinaldi, Franz-Josef Neumann, D. Christopher Metzger, Timothy Henry, David Cox, Peter L. Duffy, Ernest Mazzaferri, Claire Litherland, Roxana Mehran, Gary Mintz, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer.
Authors: Jane Hook, Sally Patricia Stenning, James Brenton, Stan B Kaye, Iain A. McNeish, Raj Naik, Timothy Perren, Jennifer Petrie, Laura Farrelly, Andrew Peter Dean, Dearbhaile M. O'Donnell, Dolores Gallardo Rincon, Jae Weon Kim, Jonathan A. Ledermann, Andrew R. Clamp
Journal: Journal of Clinical Oncology (2014)

TPS5611 Background: Three-weekly intravenous carboplatin-paclitaxel (CT) is a standard of care for the first-line treatment of ovarian cancer. Dose-dense weekly (w) CwT improved survival in the JGOG3016 trial (Katsumata, Lancet Oncol 2012) but its benefit was unclear in GOG262 (Chan, 18th ESGO Meeting 2013), as most women received bevacizumab in addition to CT or CwT. ICON8 is the largest trial of dose-dense therapy in ovarian cancer. It will compare the efficacy and safety of CT with CwT and wCwT regimens. Methods: ICON8 (NCT01654146) is a Gynecologic Cancer Intergroup, 3-stage phase III trial open at 111 centres in the UK, S Korea, Mexico, Ireland, Australia, and New Zealand. Patients (pts) with histologically proven FIGO Stage IC-IV ovarian, fallopian tube, primary peritoneal cancer or ovarian carcinosarcoma, age ≥18 years and ECOG PS 0-2 are eligible. Pts may enter after immediate primary surgery (IPS) or receive neoadjuvant chemotherapy + delayed primary surgery (DPS) after cycle 3. ICON8 is the first trial designed to permit variation in timing of surgery; randomization is stratified by IPS/DPS. Pts are randomized (1:1:1) to receive 6 21-d cycles of (1) carboplatin AUC5 + paclitaxel 175mg/m2 q3w, (2) carboplatin AUC5 q3w + paclitaxel 80mg/m2 q1w or (3) carboplatin AUC2 + paclitaxel 80mg/m2 q1w. Stage 1 (safety and feasibility) is complete (Hook, 18th ESGO Meeting 2013). The IDMC reviewed stage 2 (activity) in January 2014 and recommended that recruitment continue to all arms. Stage 3 (efficacy) is powered for dual primary outcome measures: progression free and overall survival. Secondary outcomes are toxicity, quality of life and cost effectiveness. 1,000 of 1,485 women have been recruited. Accrual is expected to complete in Q4 2014. Collection of tumor tissue, germline DNA and serial plasma is ongoing in parallel (TRICON8) with 90% pts participating. ICON8B, an extension in high risk pts comparing CwT with or without bevacizumab and CT + bevacizumab is planned. The trial is sponsored by the MRC and funded by Cancer Research UK, CRUK/10/030. Clinical trial information: NCT01654146.
TCT-121 Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock: Insights from the cVAD Registry
Authors: Mir Basir, Akshay Khandelwal, Simon Dixon, Jeffrey Moses, Brijeshwar Maini, Cindy Grines, Theodore Schreiber, E. Magnus Ohman, William O'Neill
Journal: Journal of the American College of Cardiology (2016)
ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Chronic Heart Failure
Authors: Martha J. Radford, J. Malcolm O. Arnold, Susan J. Bennett, Michael P. Cinquegrani, John G. F. Cleland, Edward P. Havranek, Paul A. Heidenreich, John D. Rutherford, John A. Spertus, Lynne Warner Stevenson, Paul A. Heidenreich, David C. Goff, Frederick L. Grover, David J. Malenka, Eric D. Peterson, Martha J. Radford, Rita F. Redberg
Journal: Circulation (2005)
TCT-584 Is there Benefit in Intravascular Ultrasound-guided Stenting in Simple Left Main Disease?
Authors: Yong Hoon Kim, Seung-Woon Rha, Ae-Young Her, Byoung Geol Choi, Jae Kyeong Byun, Se Yeon Choi, Jun Hyuk Kang, Woo Hyeun Kim, Ja Yeon Choi, James Hall, Sung Hun Park, SunKi Lee, Hu Li, Jin Oh Na, Cheol Ung Choi, Jin Won Kim, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2016)
A multicenter pilot study of adjuvant docetaxel, epirubicin and cyclophosphamide (TEC) in patients (p) with stage II/III and node-positive breast cancer (BC)
Authors: J. I. Mayordomo, A. Lorenzo, A. Modolell, I. Alvarez, J. Bayo, I. Machengs-M Centelles-K Villadiego, M. J. Rubio, L. Heras, A. Yubero, M. L. Gonzálvez, J. Valero
Journal: Journal of Clinical Oncology (2007)

11029 Background: Based on wide experience with docetaxel, adriamicin and cyclophosphamide (TAC regimen) for adjuvant therapy of node-positive BC but taking into account the high incidence of febrile neutropenia and mucositis, we performed the present study with TEC aiming for a better toxicity profile at doses equipotent to TAC. Methods: 300 p with histological diagnosis of stage II-III BC, positive axillary lymph nodes, age 18 year old, ECOG PS 0–2 and adequate bone marrow, renal, hepatic and cardiac function were accrued after surgery. Prior chemotherapy, hormone therapy and radiotherapy for BC were not allowed. Treatment: T 75 mg/m 2 iv d1, E 75 mg/m 2 iv d1 and C 500 mg/m 2 iv d1 every 21 days for 6 cycles. G-CSF 5 mcg/Kg /day s.c. was given on days 5 to 9. Results: Two hundred and one p having completed adjuvant therapy have been evaluated in this interim analysis. Median age: 53 years (range 25–77), ECOG PS 0/1 89%/11%, infiltrating ductal carcinoma 77%. Hormone receptor status was ER+ 79% and PR+ 60%. Surgery was mastectomy in 49% and conservative surgery in 51% of pts. Median number of positive axillary lymph nodes was 3. To date, 1,085 cycles were administered (median 6). Median relative dose intensity was 99% for T and 98% for E and C. There were 11 dose reductions for non- hematological toxicity and 4 for hematological toxicity. Toxicity: grade 3–4 neutropenia occurred in 15 p (7.5%), 8 of them were episodes of febrile neutropenia (4.0%). Other grade 3–4 toxicities per p were: leukopenia (7.0%), thrombocytopenia (0.5%), asthenia (6.5%), vomiting (4.5%), nausea (3.5%) and diarrhoea (3.0%). Four p (2.0%) discontinued therapy due to toxicity: 1 p with toxicodermic reaction, 1 p with hematological toxicity, 1 p with febrile neutropenia and 1 p with an allergic reaction to T. After study treatment, radiotherapy was administered to 63% of p and hormonotherapy to 66% of p. Conclusions: These preliminary results show that adjuvant TEC in p with stage II/III BC and positive axillary lymph nodes is feasible and well tolerated. No significant financial relationships to disclose.
ESFINTEROTOMIA BILIAR Y PRÓTESIS PLÁSTICA EN EL TRATAMIENTO DE LA MICROLITIASIS COLEDOCIANA
Authors: J García-Cano, D Mora Peña, R Ferri Bataller, M Del Moral Martínez, C Murillo Matamoro, Y Jiménez Martínez, M Muñoz Muñiz, L Valiente González, T Martínez Pérez
Journal: Endoscopy (2016)

Antecedentes: La ultrasonografía endoscópica y la colangiorresonancia diagnostican con frecuencia barro y microlitiasis coledociana. El tratamiento habitual sería esfinterotomía biliar y extracción con balón. Sin embargo, en muchas ocasiones el colédoco es de calibre muy fino y el paso de un balón hinchado por la papila podría causar pancreatitis. Además, en ocasiones, algunos pacientes están en lista de espera para una colecistectomía programada por colelitiasis. Nuestro objetivo fue valorar el tratamiento de la microlitiasis coledociana con esfinteroromía biliar y una prótesis plástica extraída dos meses después o previa a la colecistectomía.